Literature DB >> 20732748

Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?

Grzegorz Węgrzyn1, Joanna Jakóbkiewicz-Banecka, Magdalena Narajczyk, Andrzej Wiśniewski, Ewa Piotrowska, Magdalena Gabig-Cimińska, Anna Kloska, Monika Słomińska-Wojewódzka, Anna Korzon-Burakowska, Alicja Węgrzyn.   

Abstract

Mucopolysaccharidoses (MPS) are inherited metabolic disorders from the group of lysosomal storage diseases (LSD). They arise from mutations causing dysfunction of one of enzymes involved in degradation of glycosaminoglycans (GAGs) in lysosomes. Impaired degradation of these compounds results in their accumulation in cells and dysfunction of most tissues and organs of patients. If heparan sulfate (HS) is the sole or one of stored GAGs, brain functions are also affected. However, despite the fact that products of incomplete degradation of the same chemical, HS, are accumulated in brains of patients suffering from Hurler disease (MPS type I), Hunter disease (MPS type II), Sanfilippo disease (MPS type III) and Sly disease (MPS type VII), and obvious deterioration of brain functions occur in these patients, their behavior is considerably different between various types of MPS. Here we asked the question about biochemical reasons of these differences. We performed theoretical analysis of products of incomplete HS degradation that accumulate in tissues of patients diagnosed for these diseases. A correlation between chemical structures of incompletely degraded HS and behaviors of patients suffering from particular MPS types was found. We propose a hypothesis that particular chemical moieties occurring at the ends of incompletely degraded HS molecules may determine characteristic behavioral disturbances, perhaps due to chemical reactions interfering with functions of neurons in the brain. A possible experimental testing of this hypothesis is also proposed. If the hypothesis is true, it might shed some new light on biochemical mechanisms of behavioral problems occurring not only in MPS but also in some other diseases.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20732748     DOI: 10.1016/j.mehy.2010.07.044

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  24 in total

1.  The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients.

Authors:  Věra Malinová; Grzegorz Węgrzyn; Magdalena Narajczyk
Journal:  JIMD Rep       Date:  2011-12-11

2.  Hyaluronidase 1 and β-hexosaminidase have redundant functions in hyaluronan and chondroitin sulfate degradation.

Authors:  Lara Gushulak; Richard Hemming; Dianna Martin; Volkan Seyrantepe; Alexey Pshezhetsky; Barbara Triggs-Raine
Journal:  J Biol Chem       Date:  2012-03-26       Impact factor: 5.157

Review 3.  The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy.

Authors:  Anna-Maria Wiesinger; Brian Bigger; Roberto Giugliani; Maurizio Scarpa; Tobias Moser; Christina Lampe; Christoph Kampmann; Florian B Lagler
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

Review 4.  Chemistry and Function of Glycosaminoglycans in the Nervous System.

Authors:  Nancy B Schwartz; Miriam S Domowicz
Journal:  Adv Neurobiol       Date:  2023

5.  Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice.

Authors:  Guilherme Baldo; Fabiana Quoos Mayer; Barbara Martinelli; Anna Dilda; Fabiola Meyer; Katherine P Ponder; Roberto Giugliani; Ursula Matte
Journal:  Behav Brain Res       Date:  2012-05-09       Impact factor: 3.332

Review 6.  Mucopolysaccharidosis VII in Brazil: natural history and clinical findings.

Authors:  Roberto Giugliani; Anneliese Lopes Barth; Melissa Rossi Calvão Dumas; José Francisco da Silva Franco; Liane de Rosso Giuliani; Carlos Henrique Paiva Grangeiro; Dafne Dain Gandelman Horovitz; Chong Ae Kim; Emilia Katiane Embiruçu de Araújo Leão; Paula Frassinetti Vasconcelos de Medeiros; Diego Santana Chaves Geraldo Miguel; Maria Espírito Santo Almeida Moreira; Helena Maria Guimarães Pimentel Dos Santos; Luiz Carlos Santana da Silva; Luiz Roberto da Silva; Isabel Neves de Souza; Tatiele Nalin; Daniel Garcia
Journal:  Orphanet J Rare Dis       Date:  2021-05-22       Impact factor: 4.123

7.  Parent Experiences of Sanfilippo Syndrome Impact and Unmet Treatment Needs: A Qualitative Assessment.

Authors:  Katherine Ackerman Porter; Cara O'Neill; Elise Drake; Samantha Parker; Maria L Escolar; Stacey Montgomery; William Moon; Carolyn Worrall; Holly L Peay
Journal:  Neurol Ther       Date:  2020-12-02

8.  Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.

Authors:  Hideto Morimoto; Sachiho Kida; Eiji Yoden; Masafumi Kinoshita; Noboru Tanaka; Ryuji Yamamoto; Yuri Koshimura; Haruna Takagi; Kenichi Takahashi; Tohru Hirato; Kohtaro Minami; Hiroyuki Sonoda
Journal:  Mol Ther       Date:  2021-01-26       Impact factor: 11.454

9.  Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.

Authors:  Anna Kloska; Joanna Jakóbkiewicz-Banecka; Magdalena Narajczyk; Zyta Banecka-Majkutewicz; Grzegorz Węgrzyn
Journal:  Metab Brain Dis       Date:  2011-02-09       Impact factor: 3.584

10.  The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activation.

Authors:  Marta Moskot; Sandro Montefusco; Joanna Jakóbkiewicz-Banecka; Paweł Mozolewski; Alicja Węgrzyn; Diego Di Bernardo; Grzegorz Węgrzyn; Diego L Medina; Andrea Ballabio; Magdalena Gabig-Cimińska
Journal:  J Biol Chem       Date:  2014-04-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.